Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA supplementation and fatty acid/eicosanoid profiles in biliary atresia
jRCTs041180088Completed
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of eicosapentaenoic acid in biliary atresia (4 arms). Primary endpoint: Liver fibrosis in biliary atresia patients with or without EPA administration. Started Dec 2016; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on jRCTs041180088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180088.